Vimizim elosulfase alfa regulatory update

Japan approved Vimizim elosulfase alfa from BioMarin to treat mucopolysaccharidosis IVA (MPS IVA, Morquio’s syndrome), a rare inherited lysosomal storage disease. BioMarin said the recombinant human N...